Breakthrough Infections with SARS-CoV-2 Omicron Variant Despite Booster Dose of mRNA Vaccine
Open accessAbstract
Based on its genetic profile and preliminary in vitro and epidemiological data, the recently emerged SARS-CoV-2 Omicron variant is predicted to evade immune responses to some extent. We report a cluster of Omicron variant infections in individuals who had received full primary vaccination series and booster doses with mRNA vaccines. All patients experienced symptomatic COVID-19 but clinical manifestations were mild to moderate. Their SARS-CoV-2 viral RNA loads and anti-spike antibody levels were determined. This series proves that even three doses of mRNA vaccines may not be sufficient to prevent infection and symptomatic disease with the Omicron variant.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A third booster shot may not adequately protect against Omicron infection.
“Even a third booster shot may not adequately protect against Omicron infection 39,41”
From Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 (2022) · cites this paper as [41]
Cited by
Sorted by citations
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290 · see citing works
Ito, K., Piantham, C., & Nishiura, H. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27560 · Cited by 199 · see citing works
“Kuhlmann et al.(4) reported that Omicron infected individuals who were fully vaccinated and those who had additional booster shots.”
BackgroundStriking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2Preprint
Liu, L., Iketani, S., Guo, Y., Chan, J. F., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472719 · Cited by 142 · see citing works
Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
Peng, Q., Zhou, R., Wang, Y., Zhao, M., Liu, N., Li, S., Huang, H., Yang, D., Au, K., Wang, H., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103904 · Cited by 119 · see citing works
Emerging evidence on Omicron (B.1.1.529) SARS‐CoV‐2 variant
Sharma, V., Rai, H., Gautam, D. N. S., Prajapati, P., & Sharma, R. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27626 · Cited by 81 · see citing works
“In addition, Omicron infected people who were fully vaccinated as well as those who had additional booster shots.(51) The reproduction number of Omicron was 4.”
BackgroundAhmed, S. F., Quadeer, A. A., & McKay, M. R. (2022) · Viruses · doi:10.3390/v14010079 · Cited by 81 · see citing works
“Thus, while the number of infections may rise considerably as a consequence of Omicron’s ability to evade antibodies [23,24], robust T cell immunity provides hope that, similar to other VOCs [25], the level of protection against severe disease would remain high.”
BackgroundOmicron variant: Current insights and future directions
Rana, R., Kant, R., Huirem, R. S., Bohra, D., & Ganguly, N. K. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.127204 · Cited by 81 · see citing works
“received full primary vaccination series and booster doses of SARS-CoV-2 mRNA vaccines and experienced breakthrough infections with the Omicron variant (Kuhlmann et al., 2021).”
BackgroundKhan, N. A., Al-Thani, H. A. S., & El-Menyar, A. A. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102246 · Cited by 72 · see citing works
Tiecco, G., Storti, S., Antoni, M. D., Focà, E., Castelli, F., & Quirós-Roldán, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041987 · Cited by 58 · see citing works
“Emerging data indicate that Omicron infection occurs even in individuals who had received a full primary vaccination series and a booster dose with mRNA vaccines [24].”
BackgroundInfluentialOMICRON: Virology, immunopathogenesis, and laboratory diagnosis
Bazargan, M., Elahi, R., & Esmaeilzadeh, A. (2022) · Journal of Gene Medicine · doi:10.1002/jgm.3435 · Cited by 46 · see citing works
“infection has been recorded in people administered with the Johnson & Johnson, Pfizer–BioNTech and Oxford–AstraZeneca vaccines in South Africa, it can be concluded that Omicron infection cannot be prevented using the standard two-dose mRNA vaccine.(121,122) However, the Pfizer vaccine was reported to improve SARS-CoV-…”
MethodInterplay Between Risk Perception, Behavior, and COVID-19 Spread
Dönges, P., Wagner, J., Contreras, S., Iftekhar, E. N., Bauer, S., Mohr, S., Dehning, J., Valdez, A. S. C., Kretzschmar, M., Mäs, M., et al. (2022) · Frontiers in Physics · doi:10.3389/fphy.2022.842180 · Cited by 44 · see citing works
“[40] Constanze Kuhlmann, Carla Konstanze Mayer, Mathilda Claassen, Tongai G Maponga, Andrew D Sutherland, Tasnim Suliman, Megan Shaw, and Wolfgang Preiser.”
BackgroundSARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Diani, S., Leonardi, E. A., Cavezzi, A., Ferrari, S., Iacono, O., Limoli, A., Bouslenko, Z., Natalini, D., Conti, S., Mantovani, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216272 · Cited by 44 · see citing works
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529
Wang, Q., Anang, S., Iketani, S., Guo, Y., Liu, L., Katsamba, P. S., Shapiro, L. S., Ho, D. D., & Sodroski, J. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110924 · Cited by 32 · see citing works
“This conclusion is consistent with the increased number of vaccine breakthrough infections involving B.1.1.529 compared with earlier SARS-CoV-2 variants (Andrews et al., 2021; Kuhlmann et al., 2021; Pulliam et al., 2021).”
InfluentialMutations in SARS-CoV-2 are on the increase against the acquired immunity
Konishi, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271305 · Cited by 35 · see citing works
Roberts, D. S., Mann, M. W., Li, B. H., Kim, D., Braiser, A. R., Jin, S., & Ge, Y. (2022) · Chemical Science · doi:10.1039/d2sc02132c · Cited by 29 · see citing works
Omicron Impact in India: Analysis of the Ongoing COVID-19 Third Wave Based on Global DataPreprint
Ranjan, R. (2022) · medRxiv · doi:10.1101/2022.01.09.22268969 · Cited by 30 · see citing works
“As alluded earlier, it has been found [7] that Omicron can evade neutralizing antibodies, obtained either from the vaccination or natural infection, and thus there is a greater probability of breakthrough infections.”
BackgroundThurzo, A., Bražinová, A., Markovská, N., Waczulı́ková, I., Smatana, M., Moravanský, N., Urbanová, W., Urban, R., Strunga, M., Kurilová, V., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137693 · Cited by 29 · see citing works
“may not prevent people from becoming infected, but the observed symptoms were mild or moderate [95,96].”
BackgroundNeutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
Yahalom-Ronen, Y., Noam Erez, A., Fisher, M., Tamir, H., Politi, B., Achdout, H., Melamed, S., Glinert, I., Weiss, S., Cohen-Gihon, I., et al. (2022) · Vaccines · doi:10.3390/vaccines10020291 · Cited by 24 · see citing works
The Coming of Age of Nucleic Acid Vaccines during COVID-19
Rando, H. M., Lordan, R., Kolla, L., Sell, E., Lee, A. J., Wellhausen, N., Naik, A. S., Kamil, J. P., Gitter, A., Greene, C. S., et al. (2023) · mSystems · doi:10.1128/msystems.00928-22 · Cited by 29 · see citing works
“As of March 2022, the Omicron variant accounted for 95% of all infections sequenced in the United States (233) and was linked to an increased risk of SARS-CoV-2 reinfection (227) and further infection of those who have been vaccinated with the mRNA vaccines (234).”
Bauer, G. (2022) · Exploration of Immunology · doi:10.37349/ei.2022.00040 · Cited by 19 · see citing works
“[149] is in perfect agreement with the weekly report of the Robert Koch Institute (Germany), dated, January 27th, 2022, where it is reported that even three vaccination steps only have a marginal effect on SARS-CoV-2 omicron infection, though they established a partial protective effect towards more severe disease.”
BackgroundResultLaracy, J. C., Robilotti, E. V., Yan, J., et al. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.105 · Cited by 18 · see citing works
Infection risk of SARS-CoV-2 in a dining setting: Deposited droplets and aerosols
Ding, S., Lee, J. S., Mohamed, M. A., & Ng, B. F. (2022) · Building and Environment · doi:10.1016/j.buildenv.2022.108888 · Cited by 17 · see citing works
Mills, M. G., Hajian, P., Bakhash, S. M., Xie, H. J., Mantzke, D., Zhu, H., Perchetti, G. A., Huang, M.-L. W., Pepper, G., Jerome, K. R., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105218 · Cited by 17 · see citing works
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)Preprint
Sheward, D. J., Kim, C., Ehling, R. A., Pankow, A. P., Dopico, X. C., Martin, D. P., Reddy, S. T., Dillner, J., Hedestam, G. B. K., Albert, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.19.473354 · Cited by 17 · see citing works
Yu, Y., Liu, Y., Zhao, S., & He, D. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022485 · Cited by 11 · see citing works
Breakthrough cases of Omicron and Delta variants of SARS-CoV-2 during the fifth wave in Pakistan
Jamal, Z., Haider, M., Ikram, A., Salman, M., Rana, M. S., Rehman, Z., Haider, S. A., Ammar, M., Nisar, N., & Umair, M. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.987452 · Cited by 11 · see citing works
SARS-CoV-2 Omicron variant (B.1.1.529): A concern with immune escape
Sanyaolu, A. O., Marinkovic, A., Prakash, S., Haider, N., Williams, M., Okorie, C., Badaru, O., & Smith, S. I. (2022) · World Journal of Virology · doi:10.5501/wjv.v11.i3.137 · Cited by 8 · see citing works
Storm, N., Crossland, N. A., McKay, L. G. A., & Griffiths, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.02.482662 · Cited by 6 · see citing works
Murewanhema, G., Dzinamarira, T., Chingombe, I., et al. (2022) · COVID · doi:10.3390/covid2030023 · Cited by 6 · see citing works
Yadav, P. D., Sapkal, G. N., Sahay, R. R., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.04.031 · Cited by 6 · see citing works
Roeder, A. J., Koehler, M. A., Svarovsky, S. A., et al. (2022) · medRxiv · doi:10.1101/2022.03.03.22270812 · Cited by 4 · see citing works
Wang, H., Yang, T., Jiang, W., Qin, M., Sun, Z., Dai, W. H., & Jiang, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-19886-y · Cited by 2 · see citing works
“For the extracellular domain of the full-length spike protein (1-1208) was produced by transfecting 1 Liter ExpiCHO-STM Cells at a density of 6 × 106 cells/mL.”
MethodCorbisier, P., Petrillo, M., Querci, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4014875 · Cited by 2 · see citing works
López‐Güell, K., Prats‐Uribe, A., Català, M., et al. (2022) · medRxiv · doi:10.1101/2022.02.24.22271325
Wang, H., Yang, T., Jiang, W., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1363296/v1
Émergence des variants du SARS-CoV-2 : que peut-on espérer (ou craindre) dans un futur proche
Roche, B., & Étard, J.-F. (2021) · doi:10.64628/aak.pn64jyvmw
Complex Dynamics in the Spread of COVID-19
Contreras, S. (2023) · doi:10.53846/goediss-9876
- Authors
- Kuhlmann, C., Mayer, C. K., Claassen, M., Maponga, T. G., Sutherland, A. D., Suliman, T., Shaw, M., & Preiser, W.
- Affiliations
- LMU Klinikum (DE)
- Stellenbosch University (ZA)
- University of the Western Cape (ZA)
- Corresponding author
- Preiser, Wolfgang
- ORCID
- Venue
- SSRN Electronic Journal
- Publisher
- Elsevier BV
- Published
- 2021
- ISSN
- 1556-5068 (ISSN-L)
- OpenAlex
- W4205999879
- Cited by
- 38
- References
- 0
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 28 · 2021: 7
- Type
- posted content
- Language
- en
- Open access
- green
- doi.org
- Locations
- SSRN Electronic Journal (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- Omicron variant, breakthrough infection, mRNA vaccines, booster vaccination, vaccine efficacy, immune evasion, anti-spike antibodies, viral RNA load, COVID-19 pandemic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
